Nine Diagnostics, a leader in AI-enabled nanosensor technology, has been selected to participate in the American Cancer Society’s BrightEdge Entrepreneurs Program, a highly selective initiative designed to accelerate promising and high impact potential oncology-focused startups. This selection marks another significant milestone for Nine Diagnostics as it continues to drive innovation in cancer treatment selection, dosing, optimization, and monitoring.
The BrightEdge Entrepreneurs Program is a highly competitive initiative that provides selected startups with access to top-tier mentorship, investment opportunities, and strategic industry connections. By integrating Nine Diagnostics into this prestigious network, BrightEdge will help to support the company’s potential to transform cancer diagnostics through advanced AI and novel nanosensor technology.
Through the program, Nine Diagnostics will benefit from expert guidance, direct engagement with oncology thought leaders, and opportunities to scale its technology in collaboration with leading institutions and investors. The company is poised to leverage these resources to further its mission of transforming early cancer detection and improving patient outcomes worldwide.
“Joining the BrightEdge Entrepreneurs Program is a tremendous opportunity for Nine Diagnostics,” said Freddy T. Nguyen, MD, PhD, co-founder of Nine Diagnostics. “This recognition validates our vision and the potential impact of our AI-enabled nanosensor technology. With the support of BrightEdge, we are positioned to accelerate our innovations and bring game-changing solutions to the fight against cancer.”
Daniel Heller, PhD, co-founder of Nine Diagnostics, added, “Access to BrightEdge’s extensive network of healthcare leaders, investors, and research institutions will be invaluable as we continue to scale our platform. We are committed to advancing cutting-edge solutions that enhance cancer diagnostics, and this program brings us one step closer to making a meaningful impact in global oncology care.”
BrightEdge, the innovation and impact investment arm of the American Cancer Society (ACS), is dedicated to fostering high-potential startups that are developing breakthrough solutions in cancer treatment, diagnostics, and patient care. By supporting innovators like Nine Diagnostics, BrightEdge aims to bridge the gap between pioneering research and commercial success, ensuring that the most promising oncology technologies reach the patients who need them most.
This selection underscores Nine Diagnostics’ growing traction in the biotech sector, following its recent acceptance into the Merck Digital Sciences Studio and being awarded Novo Nordisk’s Golden Ticket at LabCentral. With its expanding portfolio of strategic partnerships and accelerator support, Nine Diagnostics is solidifying its position as a leader in next-generation cancer diagnostics, tools, and technologies.
About Nine Diagnostics
Nine Diagnostics is an AI-enabled nanosensor technology company dedicated to revolutionizing cancer detection and precision diagnostics. By harnessing machine learning, advanced computational biology, and nanosensor technology, the company is developing groundbreaking solutions for early cancer detection and real-time disease monitoring. Nine Diagnostics collaborates with top-tier research institutions, healthcare providers, and industry partners to advance next-generation diagnostic and life sciences technologies that improve patient outcomes and expand access to life-saving innovations.
